

Catalogue Number	Product	Order number / Unit
------------------	---------	---------------------

**9705 Lu-DOTA-TOC**

Reference standard for <sup>177</sup>Lu-DOTA-TOC

**Molar Mass:** 1593.58 (net peptide)

$C_{65}H_{89}LuN_{14}O_{18}S_2$

[321835-55-6] ([<sup>177</sup>Lu]-DOTA-TOC)

Colourless to off-white solid packaged in dark glass screw cap vials.

**Purity:** ≥ 95 %

**Certificates:**

CoA; MS (identity); HPLC (purity)

**Chemical Name:**

Sequence: DOTA(Lu)-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(ol), cyclic disulfide.

**Synonymes:**

natLu-Edotreotide; natLu-SMT487; natLu-DOTA-[Tyr<sup>3</sup>]octreotide; Lutetium-177Lu, [N-[2-[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl-κO]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic(2→7)-disulfidato(3-)]-; Lutetium-177Lu, [N-[[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl-κO]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic(2→7)-disulfidato(3-)]-

**Literature:**

Villard L. et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J. Clin. Oncol. 2012, 30, 1100-1106.

Please inquire for customized filling and bulk quantities.

